13 - Amyotrophic Lateral Sclerosis (ALS) Flashcards

DONT NEED TO KNOW: Groups of genes associated with ALS

1
Q

When are Babinski signs common in people?

A

Alcoholics and ALS patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

True or false? Head trauma can be linked to ALS, Parkinson’s and Alzheimer’s?

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

When is loss of child implicated in the development in sporadic ALS?

A

When it is accidental (eg. not due to cancer etc.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

True or false? Drinking reduces chance of ALS

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is amyotrophic lateral sclerosis?

A

Amyotrophic lateral sclerosis (ALS) – also referred to as motor neurone disease (MND) in most Commonwealth countries, and as Lou Gehrig’s disease in the United States – is a debilitating disease with varied etiology characterized by rapidly progressive weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking (dysarthria), difficulty swallowing (dysphagia), and difficulty breathing (dyspnea). ALS is the most common of the five motor neuron diseases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the signs and symptoms of ALS?

A
  • The disorder causes muscle weakness and atrophy throughout the body due to the degeneration of the upper and lower motor neurons.
  • Unable to function, the muscles weaken and exhibit atrophy. Individuals affected by the disorder may ultimately lose the ability to initiate and control all voluntary movement, although bladder and bowel sphincters and the muscles responsible for eye movement are usually, but not always, spared until the terminal stages of the disease.
  • Cognitive function is generally spared for most patients, although some (about 5%) also have frontotemporal dementia.
  • A higher proportion of patients (30–50%) also have more subtle cognitive changes which may go unnoticed, but are revealed by detailed neuropsychological testing.
  • Sensory nerves and the autonomic nervous system are generally unaffected, meaning the majority of people with ALS will maintain hearing, sight, touch, smell, and taste.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the pathophysiology of ALS (3)

A
  • The defining feature of ALS is the death of both upper and lower motor neurons in the motor cortex of the brain, the brain stem, and the spinal cord.
  • Prior to their destruction, motor neurons develop proteinaceous inclusions in their cell bodies and axons. This may be partly due to defects in protein degradation.
  • These inclusions often contain ubiquitin, and generally incorporate one of the ALS-associated proteins: SOD1, TAR DNA binding protein (TDP-43), or FUS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the three ALS-associated proteins?

A
  • SOD1
  • TAR DNA binding protein (TDP-43)
  • FUS

These are associated with ubiquitin to form inclusions commonly observed in ALS affected motor neurons.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What does sclerosis mean?

A

Scarring or hardening

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is FTD?

A

Frontotemporal dementia (FTD) is a neurodegenerative disease characterized by severe frontotemporal lobar degeneration. Distinguished from Alzheimer’s disease and Lewy body dementia based on the fact that it does not manifest with amyloid plaques, neurofibrillary tangles, or Lewy bodies.

Second only to Alzheimer’s disease (AD) in prevalence, FTD accounts for 20% of pre-senile dementia cases. Symptoms can begin to appear on average around 45 to 65 years of age, regardless of gender. The most common symptoms include significant changes in social and personal behavior, as well as a general blunting of emotions. Currently, there is no cure to FTD, but there are treatment options available that help alleviate the symptoms.

GGGGCC expansions of C9orf72 gene can cause ALS and FTD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is FUS?

A

RNA-binding protein FUS (Fused in Sarcoma) is a protein that in humans is encoded by the FUS gene

The disease entities which are now considered subtypes of FTLD-FUS are atypical frontotemporal lobar degeneration with ubiquitinated inclusions (aFTLD-U), NIFID (otherwise known as neurofilament inclusion body disease) and basophilic inclusion body disease (BIBD), which together with ALS-FUS comprise the FUS-opathies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Recount the abstract of the study that generated pluripotent stem cells (iPS) from an ALS patient. (5)

A
  • The generation of pluripotent stem cells from an individual patient would enable the large-scale production of the cell types affected by that patient’s disease.
  • These cells could in turn be used for disease modeling, drug discovery, and eventually autologous cell replacement therapies.
  • Although recent studies have demonstrated the reprogramming of human fibroblasts to a pluripotent state, it remains unclear whether these induced pluripotent stem (iPS) cells can be produced directly from elderly patients with chronic disease.
  • We have generated iPS cells from an 82-year-old woman diagnosed with a familial form of amyotrophic lateral sclerosis (ALS).
  • These patient-specific iPS cells possess properties of embryonic stem cells and were successfully directed to differentiate into motor neurons, the cell type destroyed in ALS.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are two alternative names for ALS?

A
  • Lou Gehrig’s disease

- Charcot’s disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the two forms of ALS?

A
  • Idiopathic (sporadic)

- Heritable (familial)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the incidence of sporadic ALS?

A

1.5-5/100,000 (1 in 1000 deaths)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What percent of ALS can run in families?

A

10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

ALS can more often be diagnosed in what gender?

A

Men, by about 1.5x

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the common age of onset of ALS?

A

55-65 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What causes most ALS patients to die?

A
  • Respiratory failure
  • Pneumonia

Only 25% survive more than 5 years post-diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are often the first symptoms of ALS? (2)

A

Difficulty in swallowing (causing weight loss) and breathing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

True or false? ALS doesn’t affect senses and bladder/bowel functions

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What does ALS selectively affect?

A

Motor neurons

Degeneration in the motor cortex: overactive tendon reflexes, Hoffmann signs, Babinski signs, clonus

Degeneration in the brain stem/spinal cord: muscle atrophy, weakness and fasciculation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

ALS motor neurons are immunopositive for what?

A

Cleaved caspase-3 protein

Triggers execution phase of apoptosis and mitochondrial accumulation around the nucleus

24
Q

There are elevated levels of what ion in sporadic ALS patients at motor neuron terminals

A

Calcium ion, overload in neurons resulting from glutamate overstimulation, inducing excitotoxicity.

25
Q

What neurotransmitter transporter do ALS patients have reduced levels of? Where?

A

Excitatory amino acid transporter 2 (EAAT2) in motor cortex and spinal cord

26
Q

Motor neurons in healthy people express constitutively low levels of inducible NO synthase (iNOS). What is observed in ALS patients?

A

Up-regulation of iNOS in motor neurons in sporadic ALS patients

27
Q

What are 5 theories for the cause of sporadic ALS?

A
  • Viral infections
  • Inflammation
  • Metal ions imbalance
  • Nutrition
  • Hormones
28
Q

List some exogenous risk factors implicated in sporadic ALS (lots)

A
  • Age at menopause
  • Dietary factors (MSG?)
  • Electrical injury
  • Family history of neurodegenerative disease
  • Geographical residence
  • Gulf war service
  • Maternal age
  • Occupation
  • Physical activity
  • Playing football professionally
  • Previous poliomyelitis infection
  • Race/ethnicity (higher in caucasians)
  • Smoking
  • Toxin exposure
  • Trauma to head
  • Years of education (higher risk with less education)
29
Q

What sort of infection is an exogenous risk factor for ALS?

A

Poliomyelitis infection

30
Q

What is β-methylamino-L-alanine (BMAA)? (3)

A
  • Found in the brains of ALS and AD patients
  • Neurodegenerative disorders are hundreds times more frequent in Guam, where BMAA is present in high concentrations in seeds of Cycas micronesica. The toxin is concentrating in the meat of bat Pteropus mariannus, which is considered a delicacy.
  • BMAA is produced in cyanobacteria and a high concentration was found in shark fins, a delicacy in Asia
31
Q

Neuronal GABAergic loss associated with cognitive performance was observed in what neurodegenerative disease?

A

ALS

32
Q

What is the SOD1 gene?

A
  • copper/zinc dependent superoxide dismutase gene
  • SOD1 is a metalloenzyme that binds on Cu and one Zn per subunit
  • Responsible for the maintenance of intracellular oxygen gas concentrations in the low range

Mutation responsible for 20% of ALS

33
Q

What is the result of mutation in the SOD1 gene?

A

Accounts for 20% of familial ALS

Hemizygous trangenic mice expessing high copy number of the G93A variant of human SOD1 become completely paralyzed and die at 16-18 weeks of age. Reduced transgene numbers have a much slower disease progression and dies at 8- 9 months.

34
Q

Knockout of what gene extends the life of G93Ahigh-mSOD1 mice (ALS model)?

A

Knockout of iNOS gene

35
Q

What is TDP-43 and what does mutation cause? What type of mutation?

A
  • Transactive response DNA-binding protein 43
  • Mutations in the glycine rich region encoded by exon 6 (C-terminal) can cause ALS
  • Mutation is dominant missense
36
Q

What do FUS/TLS mutations cause? Is it dominant or recessive?

A

FUS/TLS (fused in sarcoma/translocated in liposarcoma) are a primary cause of familial ALS. most are missense mutations and the inheritance pattern is dominant

37
Q

What did mutations in TDP-43 and FUS/TLS direct ALS research to focus on?

A

The role of RNA metabolism and processing (eg. miRNAs mediated degradation of mRNA)

38
Q

What is the proposed physiological role of TDP-43 and FUS/TLS? (6)

A
  • Transcriptional repression. FUS/TLS participate in transcription but can also act as transcriptional repressor in response to DNA damage.
  • TDP-43 and FUS/TLS regulate splicing
  • Both proteins found in a complex with Drosha (a Rnase III protein, which cleaves RNA prior to dicer), implicating a role in miRNA processing
  • Both proteins shuttle between the nucleus and the cytosol
  • They form complexes with mRNAs and other RNA in stress granules
  • Involved in spinal and axonal transport of mRNAs, where they may facilitate translation
39
Q

Which aggregate is seen in sporadic ALS and can be used as a marker for ALS?

A

TDP-43 (trans activating response DNA-binding protein 43) in anterior horn neurons

Higher proportion of TDP-43 positive cells in skin of sporadic ALS patients as well.

40
Q

Where does TDP-43 accumulate in ALS patients? The nucleus, nucleolus, or cytosol?

A

Decreased concentrations in the nucleus/nucleolus than in control, more in the cytoplasm and rough ER.

41
Q

What results in cytoplasmic accumulation of TDP-43 in ALS? (2)

A

Silencing proteins involved in nuclear transport:

  • karyopherin-β1
  • cellular apoptosis susceptibility protein (CASP)
42
Q

What pathological symptom do transgenic mice expressing mutated TDP-43 not show?

A

Cytoplasmic aggregates of TDP-43

43
Q

List 5 newly discovered mutations in familial ALS (FALS)

A
  • Optineurin (OPTN), OPTN cytoplasmic inclusions observed in sporadic ALS as well
  • Spatacsin (SPG11), autosomal recessive mutation connected to juvenile ALS
  • D-amino acid oxidase gene (R199W DAO). connected to adult onset ALS, may be linked to serine metabolism. D-serine was found in spinal cord of patients with sporadic ALS and linked to excitotoxicity
  • Charged multivesicular protein 2B (CHMP2B), autosomal-dominant mutation linked to progressive muscular atrophy
  • Paraoxonase gene cluster - three genes encoding the proteins PON1, PON2 and PON3, which are associated with high-density lipoproteins and protect against oxidation
44
Q

What are the five groups of genes associated with ALS and other syndromes?

A
  • Axonal transport
  • mRNA processing
  • Endosomal vesicle trafficking
  • Ubiquitination
  • Antioxidant
45
Q

Expansion of what gene can cause ALS and FTD (frontotemporal dementia)?

A

GGGGCC expansions of C9orf72 gene

Between 800-4400 repeats (under 25 is normal) is the most common cause of familial and sporadic ALS and familial FTD

46
Q

What are three pieces of evidence for the possible mechanism of C9orf72 expansion and its role in ALS?

A
  • 50% reduction in C9ord72 transcript levels observed in patients with expansion (loss of C9orf72 function might contribute to disease)
  • Abnormally lengthened repeats of the mutant transcript forms pathogenic foci that trap one or more RNA binding proteins
  • RAN translation, a mode of translation that occurs in the absence of an initiating ATG codon, first reported with connection to expanded CAG repeats to produce toxic polymeric peptides
47
Q

What is the one biggest drug treatment for ALS? What are three promising drugs?

A

Riluzole - Inhibits TTX sensitive sodium channels, which are up-regulated in affected neurons. Prolongs life by only 2-3 months

Promising results with:

  • AMPA antagonist
  • Glycoprotein-a neurotrophic factor
  • Dexpramipexole (neuroprotectant, improves mitochondrial function, failed phase III)
48
Q

What are three new therapies in clinical trial for ALS?

A
  • Tirasemtiv (troponin activator, increases muscle sensitivity to weak electrical impulses generated by deteriorating motor nerves)
  • NewOwn (brainstorm), a method that involves harvesting and growing patient’s mesenchymal stem cells (MSC), stimulating them to produce neurotrophic factors and transplanting them back into the spinal cord or muscles
  • Ozanezumab (monoclonal antibody against neurite outgrowth inhibitor (NOGO-A), which is overexpressed in ALS patients)
49
Q

How can siRNA be used to treat ALS?

A

Can treat autosomal dominant ALS
- SOD1 familial ALS arises through toxic gain of function mutations, rather than enzyme deficiency. I an animal model, an anti-SOD1 siRNA inhibited mutant protein production and prevented the development of clinical disease in transgenic SOD1 mutant mouse

50
Q

What three types of cell transplantation can treat ALS?

A
  • Mesenchymal stem cell transplantation into spinal cord
  • Bone marrow transplantation
  • Neural stem cell transplantation (iPSC - induced pluripotent stem cells)
51
Q

What drug, commonly used to treat bipolar disorder, may slow progression of ALS?

A

Lithium

52
Q

What are advantages and disadvantages to using induced pluripotent stem cells generated from patients with ALS to produce motor neurons?

A

Advantages: obtained cells are patient specific (fibroblasts can be turned into iPSC by delivery of Oct4, Klf4, Sox2 and c-Myc genes using viral carrier)

Disadvantages: Safety issues - difficulty with controlling of introduced oncogenic genes and retroviruses

53
Q

To induce cell differentiation of patient specific induced pluripotent stem cells, what two compounds are used? What happens once applied?

A
  • Agonist of sonic hedgehog (SHH) signalling pathway
  • Retinoic acid
  1. Embryoid bodies formed from iPS cells 5 days after seeding
  2. Embryoid bodies contain cells representative of each of the three embryonic germ layers (endoderm, mesoderm and ectoderm)
54
Q

How can iPS (induced pluripotent stem) cells by differentiated into motor neurons for treatment of ALS?

A
  • Coexpression of HB9 (a motor-neuron specific transcription factor) and TuJ1 (neuronal form of tubulin, β-tubulin)
  • Coexpression of ISL (TF involved in motor neuron development) and HB9.
  • GFAP (glial fibrillary acidic protein)
55
Q

What type of technology might allow ALS affected patients to control robotic limbs?

A

Brain-computer interface